これは幹細胞からのキメラなんで、若山さんはAC129からはキメラを作っていないと言ってるけど、嘘だとしても樹立が9/5だと実験ノートにあるのなら、キメラができたのは更にその後だということになるわね。
>>
We tested the following three different genetic backgrounds of mice for STAP stem-cell establishment from STAP cell clusters, and observed reproducible data of establishment: C57BL/6 carrying Oct4-gfp (29 of 29), 129/Sv carrying Rosa26-gfp (2 of 2) and 129/Sv × C57BL/6 carrying cag-gfp (12 of 16). STAP stem cells with all these genetic backgrounds showed chimaera-forming activity.
Breaking News: Growing Concerns Over STAP Cell Sources
＞ However, I did not make chimera from those cell lines. Then I left RIken.
" In another email he clarified: "I left Riken one year ago. Then we could
not (establish) contact well between authors. Maybe Dr. Sasai, who wrote
the papers, thought that I did chimera experiment of 129.”
前後を補うとこうだわね。
>>
The 129 strain was briefly mentioned, in both the first Nature paper, and the March 5 revised protocol of Riken’s Hitoshi Niwa (another respected stem cell scientist and co-author). In both, it was noted “reproducible establishment” of STAP cells occurred with B6, F1, and 129. “STAP stem cells with all these genetic backgrounds formed chimaera-forming activity,” both read.
The latter sentence seems to be an additional, if simple, “mistake,” Wakayama said via email. He made stem cells from the STAP cells she said came from 129 mice. But he never made chimeras from the 129 cells, as stated in the paper (and Niwa protocol). “I gave 129 mice to Dr. Obokata. Then, Dr. Obokata generated STAP cells from those mice, and gave me two STAP cells. I do not know how many STAP cells were generated at that time. I got just two. Then, I established two STAP stem cell lines from those two STAP cells. However, I did not make chimera from those cell lines. Then I left RIken." In another email he clarified: "I left Riken one year ago. Then we could not (establish) contact well between authors. Maybe Dr. Sasai, who wrote the papers, thought that I did chimera experiment of 129.”
Yoshiki Sasai, the current CDB deputy director and another respected co-author, did not immediately respond to a request for comment. Nor did Obokata.
